NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced the closing of an oversubscribed $95 million Series C financing. Proceeds from the financing will be used to support the clinical development of Ajax’s first-in-class Type II JAK2 inhibitor, AJ1‑11095, for the treatment of myelofibrosis, as well as advancing the company’s pipeline of treatments for MPNs..

纽约和剑桥，马萨诸塞州。-（商业新闻短讯）--Ajax Therapeutics，Inc.，一家为骨髓增生性肿瘤（MPNs）患者开发下一代JAK抑制剂的生物制药公司，今天宣布关闭超额认购的9500万美元C系列融资。融资收益将用于支持Ajax第一类II型JAK2抑制剂AJ1-11095的临床开发，用于治疗骨髓纤维化，并推进公司的MPN治疗管道。

The financing was led by Goldman Sachs Alternatives with participation by Eli Lilly and Company, Vivo Capital, RA Capital Management, Point72 and existing investors EcoR1 Capital, Boxer Capital, Schrödinger, Inc. and Inning One Ventures. Concurrent with the financing, Amit Sinha, Head of Life Sciences Investing and Ming Cheah, PhD, Vice President, within Life Sciences Investing at Goldman Sachs Alternatives, joined Ajax’s board of directors..

融资由高盛替代品公司牵头，礼来公司、维梧资本、RA资本管理、Point72以及现有投资者EcoR1 Capital、Boxer Capital、Schrödinger，Inc.和Inning One Ventures参与。在融资的同时，生命科学投资主管Amit Sinha和高盛替代品生命科学投资副总裁Ming Cheah博士加入了Ajax的董事会。

“We’re pleased to have attracted this level of support from such distinguished life sciences investors and biopharmaceutical companies in addition to our existing investor syndicate,” said Martin Vogelbaum, co-founder and CEO of Ajax Therapeutics. “We are now well positioned to bring much needed innovation to the field of JAK inhibitors for the treatment of MPNs and look forward to advancing AJ1‑11095 into the clinic for myelofibrosis later this year.”.

阿贾克斯治疗公司（Ajax Therapeutics）联合创始人兼首席执行官马丁·沃格尔鲍姆（Martin Vogelbaum）表示：“除了现有的投资财团之外，我们很高兴能够吸引到这些杰出的生命科学投资者和生物制药公司的支持。”。“我们现在处于有利地位，可以为治疗MPN的JAK抑制剂领域带来急需的创新，并期待着在今年晚些时候将AJ1-11095推进骨髓纤维化的临床。”

AJ1-11095 was designed by Ajax, through our collaboration with Schrödinger, using structure-based drug design and computational methods at scale, to selectively bind the Type II conformation of the JAK2 kinase and to provide greater efficacy with disease modification compared to all currently approved JAK2 inhibitors which bind the Type I conformation of JAK2.

AJ1-11095是由Ajax通过我们与Schrödinger的合作设计的，使用基于结构的药物设计和大规模计算方法，选择性结合JAK2激酶的II型构象，并与所有目前批准的JAK2抑制剂相比，在疾病修饰方面提供更大的功效。JAK2抑制剂结合JAK2的I型构象。

Additionally, AJ1-11095 has been shown in preclinical studies to maintain efficacy against MPN cells that become resistant to chronic Type I JAK2 inhibition..

此外，临床前研究表明，AJ1-11095可以维持对慢性I型JAK2抑制产生抗性的MPN细胞的疗效。

“Despite significant advances brought by the introduction of JAK inhibitors, patients with MPNs continue to have major unmet needs as current therapies, including Type I JAK2 inhibitors, often fail to provide adequate symptomatic relief and have little effect on the underlying disease,” said Amit Sinha, Head of Life Sciences Investing at Goldman Sachs Alternatives.

“尽管引入JAK抑制剂取得了重大进展，但MPN患者的主要需求仍未得到满足，因为目前的治疗方法，包括I型JAK2抑制剂，往往无法提供足够的症状缓解，对潜在疾病几乎没有影响，”高盛替代品投资生命科学负责人阿米特·辛哈（Amit Sinha）说。

“We look forward to working with Ajax’s management team to bring novel therapies, such as AJ1-11095, to patients with myelofibrosis.”.

“我们期待着与Ajax的管理团队合作，为骨髓纤维化患者带来新的治疗方法，如AJ1-11095。”

“JAK2 overactivation is central to the pathogenesis of MPNs and a Type II JAK2 inhibitor has the potential to address MPNs beyond myelofibrosis, including patients with polycythemia vera and essential thrombocythemia” said Ming Cheah, a Vice President in Life Sciences Investing at Goldman Sachs Alternatives.

高盛另类投资公司生命科学副总裁Ming Cheah表示：“JAK2过度活化是MPN发病机制的核心，II型JAK2抑制剂有可能解决骨髓纤维化以外的MPN，包括真性红细胞增多症和原发性血小板增多症患者。”

“We are proud to support the Company in delivering a new generation of transformational treatments for MPN patients.”.

“我们很骄傲地支持该公司为MPN患者提供新一代转型治疗。”

“This financing reinforces the value of Ajax’s approach to inhibiting JAK2 with its Type II inhibitor, AJ1-11095,” said Dr. Ross Levine, Ajax co-founder and Chair of Ajax’s Scientific Advisory Board, Senior Vice President for MH Translational Research and Member of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center.

阿贾克斯联合创始人兼阿贾克斯科学顾问委员会主席、MH转化研究高级副总裁、纪念斯隆·凯特琳癌症中心人类肿瘤学和发病机制项目成员罗斯·莱文博士说：“这笔资金强化了阿贾克斯用其II型抑制剂AJ1-11095抑制JAK2的方法的价值。”

“My lab has been studying Type II inhibition of JAK2 for over 10 years and we believe AJ1-11095 possesses the unique therapeutic properties and disease modifying effects of a highly selective and potent Type II JAK2 inhibitor and we’re excited to bring it to patients with MF.”.

“我的实验室已经研究了JAK2的II型抑制作用超过10年，我们相信AJ1-11095具有高度选择性和有效的II型JAK2抑制剂的独特治疗特性和疾病缓解作用，我们很高兴将其带给MF患者。”

About Ajax Therapeutics

关于Ajax Therapeutics

Ajax Therapeutics, Inc. is pursuing uniquely selective approaches to develop novel next generation therapies for myeloproliferative neoplasms (MPNs), including myelofibrosis. By combining the deep cancer and structural biology insights of our founding scientists with the industry’s most advanced computational drug discovery and protein structure platforms, we aim to discover and develop more precisely designed therapies to address the significant unmet needs for patients with MPNs..

Ajax Therapeutics，Inc.正在寻求独特的选择性方法，以开发针对骨髓增生性肿瘤（MPN）（包括骨髓纤维化）的新一代疗法。通过将我们创始科学家的深层癌症和结构生物学见解与业界最先进的计算药物发现和蛋白质结构平台相结合，我们旨在发现和开发更精确设计的疗法，以解决MPN患者的重大未满足需求。

Please find more information at www.ajaxtherapeutics.com.

请访问www.ajaxtrapeutics.com了解更多信息。

About Goldman Sachs Alternatives

关于高盛替代方案

Goldman Sachs (NYSE: GS) is one of the leading investors in alternatives globally, with over $450 billion in assets and more than 30 years of experience. The business invests in the full spectrum of alternatives including private equity, growth equity, life sciences, private credit, real estate, infrastructure, hedge funds, and sustainability.

高盛（纽约证券交易所代码：GS）是全球领先的替代品投资者之一，拥有超过4500亿美元的资产和30多年的经验。该业务投资于全方位的替代方案，包括私募股权、成长股权、生命科学、私人信贷、房地产、基础设施、对冲基金和可持续发展。

Clients access these solutions through direct strategies, customized partnerships, and open-architecture programs. The business is driven by a focus on partnership and shared success with its clients, seeking to deliver long-term investment performance drawing on its global network and deep expertise across industries and markets.

客户通过直接战略、定制合作伙伴关系和开放式体系结构计划访问这些解决方案。该业务的驱动力是专注于与客户的合作和共享成功，寻求利用其全球网络和跨行业和市场的深入专业知识提供长期投资绩效。

The alternative investments platform is part of Goldman Sachs Asset Management, which delivers investment and advisory services across public and private markets for the world’s leading institutions, financial advisors, and individuals. Goldman Sachs has over $2.8 trillion in assets under supervision globally as of March 31, 2024..

另类投资平台是高盛资产管理公司（Goldman Sachs Asset Management）的一部分，该公司为全球领先的机构、财务顾问和个人提供跨公共和私人市场的投资和咨询服务。截至2024年3月31日，高盛在全球范围内拥有超过2.8万亿美元的资产。

NOTE: Dr. Ross Levine serves on the board of directors of, has provided advisory services for, and has equity interests in Ajax Therapeutics. Dr. Levine also has intellectual property rights and interests that MSK has licensed to Ajax. MSK has intellectual property rights and other financial interests related to Ajax..

注：Ross Levine博士是Ajax Therapeutics的董事会成员，曾为其提供咨询服务，并拥有其股权。莱文博士还拥有MSK授权给Ajax的知识产权和利益。MSK拥有与Ajax相关的知识产权和其他财务利益。